Published in
Lippincott, Williams & Wilkins, Neurology: Neuroimmunology and Neuroinflammation, 1(3), p. e191, 2016
DOI: 10.1212/nxi.0000000000000191
Links
- ORCID
- Lippincott, Williams & Wilkins
- ORCID
- ORCID
- [urn.kb.se] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [curis.ku.dk] | PDF
- [umu.diva-portal.org] | PDF
Tools
Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination
,
Ann M. Dring,
Shahin Aeinehband,
Tommy Bergenheim,
Jeppe Romme Christensen,
Jeppe Romme Christensen ,
Finn Sellebjerg ,
Anders Svenningsson,
Christopher Linington,
Tomas Olsson,
Fredrik Piehl
Full text: Download
Abstract
Objective: We aimed to examine the regulation of lipocalin-2 (LCN2) in multiple sclerosis (MS) and its potential functional relevance with regard to myelination and neurodegeneration. Methods: We determined LCN2 levels in 3 different studies: (1) in CSF and plasma from a case-control study comparing patients with MS (n = 147) with controls (n = 50) and patients with relapsing-remitting MS (n = 75) with patients with progressive MS (n = 72); (2) in CSF and brain tissue microdialysates from a case series of 7 patients with progressive MS; and (3) in CSF at baseline and 60 weeks after natalizumab treatment in a cohort study of 17 patients with progressive MS. Correlation to neurofilament light, a marker of neuroaxonal injury, was tested. The effect of LCN2 on myelination and neurodegeneration was studied in a rat in vitro neuroglial cell coculture model. Results: Intrathecal production of LCN2 was increased predominantly in patients with progressive MS (p